In breast cancer, on the one hand, miR-182 targets and regulates the expression of CD3D, IL-2-inducible tyrosine kinase (ITK), FOXO1, nuclear factor of activated T cells (NFATs), TGFβ, and Toll-like receptor 4 (TLR4) to promote progression. This evidence concerns the gene TLR4 and breast carcinoma.